AIM
BPMC

Aigen Investment Management’s Blueprint Medicines BPMC Stock Holding History

Aigen Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,706
Closed -$328K – 807
2025
Q1 		$328K Sell
3,706
-779
-17% -$76K 0.05% 473
2024
Q4 		$391K Buy
+4,485
New +$411K 0.07% 405
2024
Q2 		– Sell
-4,624
Closed -$439K – 788
2024
Q1 		$439K Buy
+4,624
New +$397K 0.1% 315
2023
Q3 		– Sell
-8,635
Closed -$546K – 838
2023
Q2 		$546K Buy
+8,635
New +$469K 0.08% 327
2022
Q3 		– Sell
-13,284
Closed -$671K – 589
2022
Q2 		$671K Buy
13,284
+4,364
+49% +$256K 0.11% 245
2022
Q1 		$570K Buy
+8,920
New +$640K 0.1% 259
2021
Q3 		– Sell
-14,314
Closed -$1.26M – 482
2021
Q2 		$1.26M Buy
+14,314
New +$1.31M 0.22% 128
2020
Q2 		– Sell
-4,549
Closed -$266K – 853
2020
Q1 		$266K Buy
4,549
+4,177
+1,123% +$269K 0.04% 627
2019
Q4 		$30K Buy
+372
New +$27.9K 0.01% 871

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aigen Investment Management's BPMC Position: Q2 2025 in Review

Aigen Investment Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 3,706 shares — an estimated $328K sold.

Aigen Investment Management first reported a position in BPMC in Q4 2019 and held it in 9 quarters. The position peaked at $1.26M in Q2 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Aigen Investment Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Aigen Investment Management sold 3,706 Blueprint Medicines shares in Q2 2025, an estimated $328K.
  • Aigen Investment Management first reported a position in Blueprint Medicines in Q4 2019 and held it in 9 quarters.
  • Aigen Investment Management's Blueprint Medicines position peaked at $1.26M in Q2 2021.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Aigen Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.